Relibeta

Relibeta Uses, Dosage, Side Effects, Food Interaction and all others data.

Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.

Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin and neopterin.

Relibeta
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Relibeta
Generic	Interferon beta-1a
Interferon beta-1a Other Names	Interferon beta 1-a, Interferon beta 1a, Interferon beta-1a, Interferon beta-1a (recombinant human), Interferon beta-1a,recombinant, Interferon-beta-1a, SNG001
Weight	30mcg
Type	Injection
Formula	C₉₀₈H₁₄₀₈N₂₄₆O₂₅₂S₇
Weight	20027.0 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer	Reliance Life Science
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Relibeta is a form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis.

For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum

Relibeta is also used to associated treatment for these conditions: Relapsing Remitting Multiple Sclerosis (RRMS)

How Relibeta works

Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.

Food Interaction

Avoid excessive or chronic alcohol consumption. Alcohol and interferon beta-1a can both cause hepatoxicity, therefore if they are used together they may have additive hepatoxic effects.